Damora Therapeutics, Inc.
DMRA
NASDAQ
Healthcare
$29.98
+10.67%gain today
Market position
Market cap rank
#2152
of 2,614
1-day
+10.67%
1-month
+30.63%
6-month
+30.29%
YTD
+37.40%
1-year
+746.89%
5-year
-74.16%
Key figures
Market cap
$1.85B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-0.1
FY 2025
EPS
-$158.13
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
0.00%
FY 2025
Operating margin
0.00%
FY 2025
Net margin
0.00%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$-227.02M
FY 2025
EV / EBITDA
1.08
FY 2025
EV / Sales
0.00
FY 2025
Price / book
0.13
FY 2025
Price / sales
0.00
FY 2025
Earnings yield
-687.20%
FY 2025
FCF yield
-22.03%
FY 2025
Debt / equity
0.00
FY 2025
Current ratio
12.98
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$0
Gross profit
$0
Operating income
$-210.87M
EBITDA
$-209.76M
Net income
$-209.84M
Diluted EPS
-$158.13
Shares outstanding
1,327,039
Trading
Open
$27.09
Previous close
$27.09
Day range
$26.29 – $30.12
52-week range
$2.45 – $38.33
50-day avg
$23.89
200-day avg
$21.39
Volume
742,646
Avg volume
510,190
Beta
1.47
Price history
+746.89% over 1Y
Compare with peers
About Damora Therapeutics, Inc.
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Visit websiteCompany info
CEO
Jennifer A. Jarrett
IPO date
Mar 10, 2026
Headquarters
Waltham, MA, US
Country
US
Fundamentals are annual. Figures labeled with their fiscal year.
